{
  "docId": "019de072-0fef-7225-bee8-4eafefc8a1ee",
  "docSlug": "7f14a86c142f5693f0e80c8dcf59a0d2",
  "documentTitle": "23andMe | Investor Presentation Deck | 63 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 63,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The chart shows tumor growth inhibition over time, highlighting the triple combination (Anti-CD96 + Anti-TIGIT + Anti-PD1) as the most effective.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0fef-7225-bee8-4eafefc8a1ee/40",
  "deckHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee",
  "deckJsonHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee.json",
  "deckAnchorHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.45,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "chart",
      "text": "CD96, TIGIT and PD-1 Combination Suggests Synergy",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79abc104-4b2d-4dd2-bb22-74e7805a6ff8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Cancer Immunol Res. 2019;7(4):559",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05c49bb7-95c3-49f2-a0e0-93e0b31c0e7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.4
      },
      "kind": "table",
      "text": "CD226 axis components owned by GSK",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bac1b32e-9032-4370-873f-7bbf35487d5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Preclinical Data Supports Combining CD96 with PD-1 and TIGIT Inhibitors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab1cbb6a-3968-4800-abe8-78df1f7ffe65",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Evidence Matrix",
      "slug": "evidence-matrix",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "621e3171-f412-42f0-baf4-770134d99cf1",
      "evidence": "The slide presents a table of data and a chart showing preclinical data supporting the combination of CD96 with PD-1 and TIGIT inhibitors.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}